Magnesium and glycemic control: what the 2025 meta-analysis actually found

Observational data have linked low magnesium status to type 2 diabetes for forty years. The supplementation literature has been messier — small trials, mixed magnesium forms, heterogeneous populations, and headline-friendly press releases. A 2025 systematic review and meta-analysis of 35 randomized trials gives the field its clearest summary to date and a more honest answer than either advocates or skeptics typically present.

Why magnesium plausibly matters for glucose

Magnesium is a required cofactor for the tyrosine kinase activity of the insulin receptor. Intracellular magnesium deficiency impairs insulin signaling and is associated with insulin resistance in both metabolic and isotope-clamp studies [1]. About 25–40% of people with type 2 diabetes have low serum or red blood cell magnesium, in part because hyperglycemia drives urinary magnesium loss. The biologic plausibility is therefore strong, but biologic plausibility does not predict trial response.

The 2025 meta-analysis

The pooled analysis included 35 RCTs in adults with type 2 diabetes, prediabetes, or insulin resistance, with durations from 6 weeks to 12 months and doses of elemental magnesium from 150 to 500 mg/day. The headline finding: magnesium supplementation reduced fasting plasma glucose by approximately 8.2 mg/dL (95% CI -12.4 to -4.0) and HbA1c by 0.31% (95% CI -0.47 to -0.15) on average [2]. Insulin sensitivity improved modestly on HOMA-IR. The effect was concentrated in participants with low baseline magnesium status and in trials lasting at least 12 weeks.

Putting 0.31% HbA1c in context

An HbA1c reduction of 0.3% is modest relative to first-line pharmacotherapy: metformin typically reduces HbA1c by 1.0–1.5%, SGLT2 inhibitors by 0.7–1.0%, GLP-1 agonists by 1.0–1.8%. Magnesium's effect is closer to that of a behavioral intervention such as a structured exercise program. It is real but should not be sold as a glucose-lowering drug equivalent. Where magnesium is more interesting is as an adjunct in patients with documented hypomagnesemia, where correction of the deficit may produce its full pharmacologic effect [3].

Which magnesium form was used

The trials included magnesium chloride, sulfate, oxide, citrate, aspartate, and lactate. Subgroup analysis did not show a clear superiority of any single form for glucose outcomes, though oxide trials trended weaker — consistent with its poorer bioavailability. The 2025 meta-analysis explicitly noted that comparative head-to-head data between forms are still scarce, so the choice between citrate, glycinate, or other forms should be driven more by tolerability and other indications (sleep, constipation, migraine) than by glycemic priority [4].

Who should consider supplementation

The trial-supported population is adults with type 2 diabetes or prediabetes who have laboratory evidence of magnesium deficiency (serum below 1.8 mg/dL, or red blood cell magnesium below the reference range), or who consume substantially less than the RDA (310–420 mg/day depending on age and sex). Doses of 200–400 mg of elemental magnesium daily for at least 12 weeks are the trial-relevant exposure. Supplementing without low baseline status produced more variable and generally smaller effects in the meta-analysis [5].

Safety and interactions

Magnesium supplementation is generally safe in adults with normal kidney function. In chronic kidney disease (eGFR <30 mL/min/1.73m²), supplementation can produce dangerous hypermagnesemia because renal excretion is the primary elimination route. Magnesium reduces the absorption of bisphosphonates, levothyroxine, certain antibiotics (tetracyclines, fluoroquinolones), and gabapentin — these should be separated by 2–4 hours. The most common dose-limiting side effect is loose stool, which is more pronounced with oxide and citrate forms [6].

The bottom line

The 2025 meta-analysis confirms a modest, real effect of magnesium supplementation on glycemic control — roughly 0.3% HbA1c on average, concentrated in patients with low baseline status and longer trial durations. This is not a substitute for guideline-directed diabetes therapy, but it is a defensible adjunct in patients with documented deficiency or persistent suboptimal intake. The form matters less than the dose, the duration, and the baseline status. Patients with kidney disease should not self-supplement without monitoring.